Publications by authors named "E N Berezin"
Gram-negative bacteria (GNB) are a major cause of neonatal sepsis in low- and middle-income countries (LMICs). Although the World Health Organization (WHO) reports that over 80% of these sepsis deaths could be prevented through improved treatment, the efficacy of the currently recommended first- and second-line treatment regimens for this condition is increasingly affected by high rates of drug resistance. Here we assess three well known antibiotics, fosfomycin, flomoxef and amikacin, in combination as potential antibiotic treatment regimens by investigating the drug resistance and genetic profiles of commonly isolated GNB causing neonatal sepsis in LMICs.
View Article and Find Full Text PDFArticle Synopsis
- Tuberculosis poses a risk of reactivation in Multiple Sclerosis patients receiving immunosuppressant therapy, highlighting the need for diagnosis and treatment of Latent Tuberculosis Infection (LTBI).
- A cross-sectional study conducted on 58 MS patients from February 2021 to June 2023 found that 29.3% were diagnosed with LTBI, with a majority being female and under immunomodulating treatments.
- The treatment for LTBI was generally safe, with most patients receiving Isoniazid, although a small percentage experienced hepatotoxicity.
Risks of low vaccination coverage and strategies to prevent the resurgence of vaccine-preventable diseases in infants in the COVID-19 pandemic scenario: recommendations for Latin America and the Caribbean by the group of experts on infant immunization for Latin America.
Expert Rev Vaccines
November 2023
Article Synopsis
- * In 2021, experts from 13 countries in the region gathered to address vaccination challenges and propose strategies to prevent the return of vaccine-preventable diseases.
- * Suggested strategies for increasing vaccination coverage include using combination vaccines, enhancing surveillance, improving school engagement, promoting vaccine education and equity, and fostering collaborations among medical societies.
Background: There is limited data on antibiotic treatment in hospitalized neonates in low- and middle-income countries (LMICs). We aimed to describe patterns of antibiotic use, pathogens, and clinical outcomes, and to develop a severity score predicting mortality in neonatal sepsis to inform future clinical trial design.
Methods And Findings: Hospitalized infants <60 days with clinical sepsis were enrolled during 2018 to 2020 by 19 sites in 11 countries (mainly Asia and Africa).
Neonatal sepsis is a significant cause of mortality and morbidity in low- and middle-income countries. To deliver high-quality data studies and inform future trials, it is crucial to understand the challenges encountered when managing global multi-centre research studies and to identify solutions that can feasibly be implemented in these settings. This paper provides an overview of the complexities faced by diverse research teams in different countries and regions, together with actions implemented to achieve pragmatic study management of a large multi-centre observational study of neonatal sepsis.
View Article and Find Full Text PDF